Ditch Labs is thrilled to announce a transformative milestone in its mission to tackle one of the most pressing public health challenges of our time: nicotine addiction. The company has successfully raised $5,700,000 in its latest funding round, a significant endorsement from investors who recognize the potential of Ditch Labs’ innovative approach to nicotine cessation. For too long, traditional Nicotine Replacement Therapies (NRTs) have fallen short due to issues such as poor adherence, imprecise dosing, and an inability to address the complex behavioral dimensions of smoking and vaping addiction. With over 8 million deaths attributed to nicotine-related causes annually, and more than 1.2 billion people continuing to smoke worldwide, the need for a scientifically advanced solution has never been more urgent.
Ditch Labs is stepping up to the challenge with its groundbreaking DitchPen®, a proprietary inhaled NRT device engineered to mimic the pharmacokinetic profile of smoking, ensuring effective craving relief and withdrawal management. The DitchPen® delivers a controlled, stepwise reduction of nicotine, facilitating sustained cessation while addressing the behavioral components of addiction through a complementary digital therapeutic application. This cutting-edge system provides structured dose reduction protocols and real-time behavioral support, empowering users with the tools needed for a successful quit journey.
The newly raised capital will be instrumental in scaling production capabilities, further refining device technology, and expanding clinical trials and digital support platforms. Ditch Labs remains committed to pioneering the next generation of nicotine cessation therapies and making a meaningful impact on reducing the global burden of tobacco-related disease and mortality.
